BCL2L11 and cancer: MiR423-3p was previously demonstrated to inhibit Bim, an important pro-apoptotic protein in cancers (X. Li et al., 2021), which has been demonstrated to be down-modulated in a slow-progressing ALS mouse model (Matus et al., 2013).